Taiga Biotechnologies, Inc. is developing a new class of cell-based therapies utilizing autologous immune cells and allogeneic stem cells. New class of cellular therapy, with an agnostic approach. Product manufacturing time - less than 24 hours. Access to global markets with active clinical trials.
Aurora, United States
Founded in 2006
11-50 Employees
Working industry
Biotechnology
Type of company
Manufacturer
Ownership structure
Privately Held
Locations
1 Headquarter
Number of products
1 Product
Specialised areas
Biotechnology, Life Science, Therapeutics
Taiga Biotechnologies offers a wide range of products and services
Product
Pipeline | Taiga Biotechnologies, Inc.
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Taiga Biotechnologies operates in 1 country around the world
Get an overview of the locations of Taiga Biotechnologies
Location
Country
State
City
Headquarter
United States
Colorado
Aurora
Some frequent questions that have been asked about Taiga Biotechnologies
Where is Taiga Biotechnologies located?
The company headquarter of Taiga Biotechnologies is located in Aurora, Colorado, United States. It's worth noting, that the company may have more locations
How many employees does Taiga Biotechnologies approximately have?
As of the latest available information Taiga Biotechnologies has around 11-50 employees worldwide.
When was Taiga Biotechnologies founded?
Taiga Biotechnologies was founded in 2006
In which industries does Taiga Biotechnologies mainly work?
The company Taiga Biotechnologies has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Taiga Biotechnologies
Cell BioEngines LLC
Boston, United States
1-10 Employees
2020
We Develop Cell-based Products Both Within Our Company and Through Our Partner Company. We are therapeutic area agnostic which allows us maximum flexibility to focus on advancing cutting-edge cell-based immuno-therapeutics approaches in oncology across multiple types of solid cancer. Cell BioEngines, Inc., is a clinical-stage biotech company focused on developing 'off-the-shelf' allogeneic cell therapies as 'drugs' to turn all cancers into curable diseases. Established in December 2022, the company's revolutionary science includes single cell discoveries from Harvard Medical School, and in-licensing manufacturing process technology from Icahn School of Medicine at Mount Sinai. Stem Cells Expansion and Differentiation to Manufacture Potent Cells for Clinical Use. Cellular Immunotherapy Product Candidates to Transform Medicine and Healthcare. Allows us to pursue a broad range of products and product candidates with high clinical and commercial potential. Low cost manufacturing enables us to act quickly to seize time-sensitive opportunities and provides us with a wider range of options from which to select the most ideal financial structure for each product.
TC BioPharm
Holytown, United Kingdom
11-50 Employees
2013
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. Our mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life. We are committed to bringing improved medicines to patients as quickly as possible by creating efficient product development and clinical translation processes. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. Established in 2014, we have expanded into 5 global locations and have grown to over 100 employees. TC BioPharm received a license from MHRA to produce gamma delta T cell therapy products at its clinical manufacturing facility near Glasgow, UK. This was an adaptive clinical trial for TC BioPharm’s autologous gamma delta T cell product for melanoma, lung and kidney cancer.
Triumvira Immunologics
Austin, United States
11-50 Employees
2015
We are developing multiple TAC-based therapeutic candidates using both autologous and allogeneic manufacturing approaches. We leverage the most advanced manufacturing technologies for optimum product quality.
BioGenCell
Netanya, Israel
1-10 Employees
2008
Our mission is to make personalized cell therapy a reality for patients worldwide, providing accessible treatments to various unmet needs. Meet the people behind BioGenCell: A Group of Dedicated BioMed, Healthcare, Vascular and Business Professionals, Including a Nobel Prize Laureate and World-Renowned Scientists. BioGenCell is dedicated to changing the lives of patients suffering from degenerative microvascular diseases, stopping disease progression, reversing disability, reducing pain, and enhancing functionality. BioGenCell’s groundbreaking cell-therapy treatments aim to provide more accessible, reliable and cost-effective therapeutic options, with the hope of significantly impacting these tragic figures. BioGenCell’s Phase 2 Clinical Trial assesses the safety and efficacy of the BGC101 cell therapy in treating Chronic Limb-Threatening Ischemia. Since its inception in 2008, BioGenCell has been committed to transforming the lives of patients with degenerative diseases through advanced cell therapy treatments, based on the Company’s groundbreaking TRACT technology that uses a patient’s own blood as personalized medicine. Our innovative TRACT technology allows for stem cell therapies that are patient-friendly and physician-friendly. Through advanced, standardized procedures, we are dedicated to bringing transformative cell therapy treatments to vascular physicians and surgeons, podiatrists, and various other healthcare providers and clinicians.
Rebirthel
Kyoto, Japan
1-10 Employees
2019
Rebirthel aims to realize cell-based therapies against cancer or other immune-related diseases by using universal T cells that are regenerated from pluripotent stem cells. To solve these problems, Rebirthel provides “off-the-shelf T cells” that can be universally used with any patients in an allogeneic setting. Rebirthel has already established a method by which potent killer T cells can be produced in vitro from iPS cells. Using this method, Rebirthel is now developing a strategy where tumor antigen-specific T cells are mass-produced and transfused to patients as off-the-shelf T cells. Rebirthel opens the way to a future when patients go to hospital to receive transfusion of T cells to treat their disease. Rebirthel was founded in October 2019 with the aim of providing novel treatments against cancer, infectious diseases, and other immune-related diseases. Rebirthel is one of the leading companies in the field of immunotherapy and has multiple globally patented technologies. Rebirthel operationalizes cell-based cancer immunotherapies developed by Professor Hiroshi Kawamoto (Institute for Frontier Life and Medical Sciences, Kyoto University).Rebirthel will provide “universal” cytotoxic T lymphocytes regenerated from pluripotent stem cells, to be used as “off-the-shelf T cells” in cancer immunotherapy.
Safi Biosolutions
Arlington, United States
1-10 Employees
2019
As the cell therapy commercialization partner of a 5-year Department of Defense program to manufacture on-demand blood products, Safi Biotherapeutics and its collaborators are working to ‘crack the code’ of Cell Therapy 2.0 challenges of manufacturing at appropriate scale, high consistency of product, and economically viable cost of goods by integrating world-leading expertise in cord blood stem cell expansion, bioprocessing optimization, manufacturing scale-up and cryostorage. Lead development programs for manufactured, on-demand cell therapy products include red blood cells for trauma, tailored red blood cells for specific transfusions (e.g. The co-founders and leadership team at Safi Biotherapeutics bring experience in ex vivo human blood cell development, biologic and pharmaceutical manufacturing, pre-clinical and clinical development, and regulatory submissions.